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Abstract
Purpose Elevated triglycerides (TG) and low high-density
lipoprotein cholesterol (HDL-C) levels contribute to cardio-
vascular disease risk and can be effectively treated with feno-
fibric acid. A trial is under way to evaluate the effect of once-
daily fenofibric acid or placebo on carotid intima-media thick-
ness (CIMT) progression in patients with controlled low-
density lipoprotein cholesterol (LDL-C) levels achieved
through atorvastatin treatment, but with high TG and low
HDL-C levels.
Methods In this multicenter, double-blind study, 682 patients
were randomized to once-daily delayed-release capsules of
choline fenofibrate 135 mg (fenofibric acid [Trilipix®; Abbott,
North Chicago, IL]) or placebo plus atorvastatin treatment after
a 2- to 10-week diet and atorvastatin run-in period. Key inclu-
sion criteria included age ≥45 years; posterior-wall common
CIMT ≥0.7 mm on at least one side at baseline; fasting results
of TG ≥150 mg/dL, and HDL-C ≤45 mg/dL for men or HDL-
C ≤55 mg/dL for women at screening while receiving atorva-
statin; controlled LDL-C; and known coronary heart disease
(CHD) or a CHD risk equivalent. The primary efficacy vari-
able is the rate of change from baseline through week 104 in
the mean posterior-wall intima-media thickness of the com-
mon carotid arteries (composite value of left and right sides).
Conclusions This trial is the first to examine the effect of
fenofibric acid on CIMT and the first CIMT trial to select
patients with controlled LDL-C and elevated TG and low
HDL-C as inclusion criteria. Also, this trial will prospec-
tively evaluate the effect of treatment on LDL particles and
address shortcomings of previous CIMT trials.
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Introduction
Herein we present the rationale and design of a trial with the
objective of evaluating the effect of once-daily fenofibric
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acid or placebo, in addition to atorvastatin therapy, on ca-
rotid intima-media thickness (CIMT) progression in a pop-
ulation of patients with mixed (type IIb) dyslipidemia who
have achieved low-density lipoprotein cholesterol (LDL-C)
goals while receiving atorvastatin.
The association of elevated LDL-C with coronary heart
disease (CHD) risk and the reduction of LDL-C with statin
therapy are well documented. However, it is clear that the
reduction of LDL-C by statin therapy alone does not always
adequately reduce the risk of cardiovascular disease (CVD).
In a review of several studies, Fruchart et al. reported the
percentage of residual risk ranges from 63 % to 91 % [1],
meaning that even when CVD events are reduced by reach-
ing optimal LDL-C levels with statin therapy, many patients
will still experience a CVD event. Factors contributing to
residual risk include poor nutrition, lack of exercise, and
dysregulation of lipids other than LDL-C (eg, high-density
lipoprotein cholesterol [HDL-C] and triglycerides [TG]) [1].
Patients with mixed dyslipidemia (high LDL-C, low
HDL-C, and high TG) may benefit from treatments that do
more than just primarily lower LDL-C. One such treatment
option is fenofibrate, or its active metabolite, fenofibric acid,
which increases HDL-C and lowers TG. In a meta-analysis
of 18 randomized controlled trials, fibrate monotherapy was
found to significantly reduce major cardiovascular (CV)
events, coronary events, and non-fatal coronary events com-
pared with placebo [2]. For fenofibrate specifically, results
from the ACCORD study determined that of patients treated
only with simvastatin, the CVD event rate in the subset of
patients with mixed dyslipidemia (TG ≥204 mg/dL and
HDL-C ≤34 mg/dL) was quite high compared with the
remainder of the patient population (17.3 % vs 10.1 %,
respectively); add-on fenofibrate therapy resulted in a lower
CVD event rate of 12.4 % in this mixed dyslipidemia subset
[3]. In addition, in a post hoc analysis of the FIELD study,
an apparent benefit of fenofibrate monotherapy treatment on
CVD risk, relative to placebo, in patients with type 2 diabe-
tes treated for a median of 5 years was observed in those
with baseline TG ≥204 mg/dL and HDL-C <40 mg/dL for
men and <50 mg/dL for women [4]. These possible benefits
of fenofibrate therapy in the ACCORD and FIELD studies
were only observed in the mixed dyslipidemia subgroups,
whereas no significant reductions in CVD event rates were
observed in the overall study populations [3, 5].
Another meta-analysis that included a total of 4,726
patients from the ACCORD and FIELD studies, as well
as 3 studies on the fibrates gemfibrozil and bezafibrate,
specifically evaluated treatment effect on coronary out-
comes in the subsets of patients with mixed dyslipide-
mia, defined as TG ≥204 mg/dL and HDL-C ≤34 mg/dL
[6]. The odds of experiencing a CHD event were re-
duced with fibrate treatment by 35 % compared with
placebo in the dyslipidemia cohort, and only 6 % in a
matched cohort without dyslipidemia. These data high-
light the potential benefit of fibrate treatment for patients
with mixed dyslipidemia, but until now, no clinical study
has been designed to specifically evaluate the effect of
fibrates in this population.
Warnings concerning a possible increased risk for
muscle-related adverse events associated with a combina-
tion of fibrate and statin have limited its use; however,
long-term studies with a choline salt of fenofibric acid or
fenofibrate and statin therapy have demonstrated that this
combination is generally well tolerated [3, 5, 7–11]. The
incidence of muscle-related adverse events was similar
between combination treatment and statin monotherapy
[9]. Thus, the Food and Drug Administration has ap-
proved an indication for the choline salt of fenofibric
acid formulated as delayed-release mini-tablets in a cap-
sule (fenofibric acid [Trilipix®]; Abbott, North Chicago,
IL) for use in combination with a statin to reduce TG and
increase HDL-C in patients with mixed dyslipidemia and
CHD or a CHD risk equivalent who are on optimal statin
therapy to achieve their LDL-C goal [12]. Several 12-
week controlled studies of combination fenofibric acid
plus statin therapy have demonstrated significant benefits
on HDL-C, TG, non-HDL-C, apolipoprotein (Apo) B,
and very low-density lipoprotein cholesterol (VLDL-C)
levels compared with statin treatment alone [13–16].
These benefits were maintained for at least 2 years [17]
and were also demonstrated in subpopulations of patients
with diabetes mellitus or persistently elevated TG [18,
19]. Safety profiles were similar between combination
treatments and monotherapies, with no unexpected safety
signals relative to each of the monotherapies.
Carotid intima-media thickness is a measure of subclin-
ical atherosclerosis. The association between CVD and
CIMT is well established, with abundant evidence that in-
creased CIMT is a risk factor for CV events [20–23]. Pre-
dictors of CIMT progression have included elevated TG,
non-HDL-C, Apo B, and various lipid ratios in patients with
moderate CHD risk [24]. CIMT can also be used as a tool
for CVD risk assessment [25–27]. Many CVD drug studies
have utilized CIMT as a clinical endpoint, although there are
differing opinions on the validity of CIMT as a surrogate
marker for outcome studies [28, 29]. A unique aspect of the
current study is that it is the first to include only patients
with high TG, low HDL-C, and controlled LDL-C. The
selection of this patient population will enable further elu-
cidation of the relationship between the pharmacologic
modifications of TG and HDL-C, and the progression of
atherosclerosis.
A previous study investigated the effect of fenofibrate
plus antihypertensive treatment on CIMT in 225 patients
with essential hypertension and high TG [30]. After 2 years
of combination treatment, CIMT measures either remained
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stable or regressed. In contrast, patients on antihypertensive
therapy alone had significant progression of CIMT measures.
Also of note, treatment with fenofibrate alone in a study
population with type 2 diabetes and normal TG and HDL-C
did not affect CIMT, but did significantly reduce TG com-
pared with baseline (P<0.001) [31].
An abundance of small LDL particles is common in
patients with elevated TG and low HDL-C. These small
particles may be particularly atherogenic because of their
greater propensity to enter the arterial wall, where they
can undergo oxidation and stimulate endothelial cell pro-
duction of inflammatory proteins and procoagulants [32].
Uncertainty remains as to whether LDL size is indepen-
dently associated with CVD risk after adjusting for the
LDL particle concentration. The current study will pro-
spectively evaluate the effect of fenofibric acid treatment
on LDL particle size and concentration, providing an
opportunity to assess the relationships between LDL par-
ticle concentration and size, as well as changes in these
parameters and risk for CIMT progression.
The current trial was designed to address some of the
limitations of previous CIMT trials. For example, patients
selected for the trial should be at high risk for CIMT pro-
gression and have sufficient CIMT thickness to allow po-
tential for CIMT regression. The lack of a minimum CIMT
thickness entry criterion has been suggested as a possible
reason patients in the ENHANCE trial did not exhibit sig-
nificant improvement in CIMT in response to ezetimibe plus
simvastatin treatment compared with simvastatin alone [33].
In contrast, other trials with minimum CIMT requirements
have demonstrated significant treatment-specific CIMT
reductions [34, 35]. The current trial only includes patients
with an increased CIMT (common carotid ≥0.7 mm) at
baseline, which may increase the probability of detecting a
treatment effect.
In the current study, particular consideration was given to
the assumptions included in the power analysis. Thirteen
studies that used simple mean change from baseline (7
studies) or regression models (6 studies) were analyzed to
determine the common standard deviation (SD) for the
annual progression rate (Table 1) [31, 34–46]. Regression-
based models would generally be expected to result in
smaller SDs because they reduce the unexplained variance
due to the correlation of the repeated measures within each
patient. The median SD from the studies using regression
models was substantially lower (0.028) than that for the
studies analyzing the simple mean change from baseline
(0.076). Thus, the assumption of SD00.045 in this study
is expected to be conservative due to the use of the mixed-
model regression analysis.
The hypothesis for the current study is that patients with
mixed dyslipidemia treated with a statin to reach prespeci-
fied LDL-C levels, but with persistent high TG and low
HDL-C levels, will experience CIMT benefits from the
lipid-altering effects of fenofibric acid.
Methods
Study design
This is a randomized, multicenter, prospective, double-
blind, placebo-controlled, phase III study of 682 patients
in the United States (80 sites in 12 geographic locations;
ClinicalTrials.gov identifier: NCT00616772). The planned
duration of the study is 118 weeks, composed of a 2- to 10-
week diet and atorvastatin run-in period, a 104-week treat-
ment period, and a 30-day safety follow-up period (Fig. 1).
The estimated study completion date is August 2012. Writ-
ten informed consent was obtained from all patients, and
institutional review board approval of the protocol and
informed consent form was obtained from each study site.
Key inclusion/exclusion criteria
Patients meeting the following criteria were included: age
≥45 years at visit 1; posterior-wall intima-media thickness
(IMT) of the common carotid artery (CCA) ≥0.7 mm on one
side at baseline; TG ≥150 mg/dL and HDL-C ≤45 mg/dL for
men or HDL-C ≤55 mg/dL for women after a ≥12-hour
fasting period at screening; LDL-C ≤100 mg/dL at visit 1,
1a, 1b, or 1c AND an average of 2 consecutive LDL-C
values ≤105 mg/dL from visits 1, 1a, 1b, 1c, and visit 2.
Patients were also required to have known CHD or a CHD
risk equivalent. Patients with any of the following were
excluded from the study: systolic blood pressure >140 mm
Hg or diastolic blood pressure >90 mm Hg at screening,
type 1 diabetes mellitus, diabetic ketoacidosis, or uncon-
trolled type 2 diabetes mellitus (HbA1c of >10.5 %).
Randomization procedure
A randomization schedule stratified by baseline atorva-
statin dose assigned patient numbers to blinded treatment
assignments (fenofibric acid or placebo) in a 1:1 ratio. An
additional randomization schedule assigned study drug
bottle numbers to blinded treatment assignments, and a
random subset of study drug bottles were then supplied to
each site. At visit 1, the patient was assigned a unique
screening number through the use of an Interactive Voice
Response System (IVRS). At baseline, the assigned
screening number and the current atorvastatin dose was
given to the IVRS by the site. The IVRS then assigned a
4-digit patient number and one of the study drug bottle
numbers corresponding to the randomized treatment as-
signment to each patient.
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Table 1 Comparison of baseline lipid levels and mean common CIMT progression rates from clinical studies used to calculate the power analysis
standard deviation











Taylor et al. (2004) [37]
Niacin 87 39 154 12 months 0.014 (0.104)
Placebo 91 40 172 0.044 (0.100)
Difference −0.03
Sidhu et al. (2004) [44]
Rosiglitazone 98 45 114 48 weeks −0.012 (0.094)
Placebo 102 47 137 0.031 (0.096)
Difference −0.043
Hanefeld et al. (2004) [46]
Acarbose Not 51 212 ≥36 months 0.007 (0.019)b
Placebo reported 49 235 0.013 (0.018)b
Difference −0.006b
Mazzone et al. (2006) [36]
Pioglitazone 113.8 47.1 178.6 72 weeks −0.001
Glimepiride 111.3 47.6 170.4 0.012
Difference −0.013
Hodis et al. (2006) [42]
Troglitazone 170 50 115 24 months 0.0030 (0.021)b
Placebo 182 50 115 0.0066 (0.021)b
Difference −0.0036b
Hedblad et al. (2007) [41]
Rosiglitazone 135 50 150 12 months 0.01 (0.073)
Placebo 131 50 150 0.017 (0.076)
Difference −0.007
Crouse et al. (2007) [34]
Rosuvastatin 155 50 126 24 months 0.0004 (0.019)b
Placebo 154 49 134 0.0088 (0.02)b
Difference −0.0085b
Kastelein et al. (2007) [38]
Atorvastatin 139 52 97c 24 months −0.0014 (0.027)b
Atorvastatin + torcetrapib 138 53 97c 0.0038 (0.027)b
Difference −0.0052b
Kastelein et al. (2008) [43]
Simvastatin 318 47 160c 24 months 0.0024 (0.077)
Simvastatin + ezetimibe 319 47 157c 0.0019 (0.079)
Difference 0.0005
Hiukka et al. (2008) [31]
Fenofibrate 120 45 136 60 months 0.0050 (0.060)b
Placebo 118 43 147 0.0069 (0.054)b
Difference −0.0019b
Meuwese et al. (2009) [35]
Pactimibe 141 51 135 12 months 0.019 (0.099)d
Placebo 139 52 136 0.005 (0.085)d
Difference 0.014
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Study phases
Screening phase
At visit 1 (prescreening), all patients had a fasting blood sample
drawn for blood chemistry, HDL-C, TG, and LDL-C levels.
Patients currently taking atorvastatin and with a LDL-C level of
≤100 mg/dL (goal LDL-C) proceeded to visit 2 (screening)
within 1 to 2 weeks. Patients currently taking atorvastatin, but
with an LDL-C level of >100mg/dL, had their atorvastatin dose
titrated to reach their LDL-C goals. Up to 3 visits (visit 1a, b, and
c) separated by approximately 2 weeks were allowed to achieve
the LDL-C goal before proceeding to visit 2 (within 1–2 weeks
of achieving the LDL-C goal). Patients not currently taking
atorvastatin discontinued other statins and began treatment with
atorvastatin, with up to 3 visits (visit 1a, b, and c) approximately
2 weeks apart allowed for dose titration to achieve their LDL-C
goal before visit 2. All patients must have been taking atorva-
statin for at least 4 weeks before visit 3 (baseline). During the
screening phase, all patients also initiated a diet recommended
by the American Heart Association [47].
Treatment phase
At baseline, patients were randomly assigned to either a once-
daily delayed-release capsule of choline fenofibrate 135 mg
(fenofibric acid [Trilipix®]) or once-daily placebo in addition
to atorvastatin treatment. To maintain an LDL-C value of
<130 mg/dL, investigators reinforced diet requirements and
adjusted the atorvastatin dose (maximum dose 40 mg/d). The
addition of ezetimibe (10 mg) was allowed if the patient was
already at the maximum atorvastatin dose. To ensure all
Fig. 1 Study design
Table 1 (continued)











Taylor et al. (2009) [45]
Ezetimibe 84 43 122c 14 months −0.0007 (0.037)
Niacin 81 43 126c −0.0142 (0.040)
Difference 0.0135
Davidson et al. (2009) [40]
Pomegranate juice 139 55 153 18 months 0.005 (0.048)b
Control 142 56 144 0.005 (0.048)b
Difference 0.00b
C cholesterol; CIMT carotid intima-media thickness; HDL high-density lipoprotein; LDL low-density lipoprotein; TG triglyceride
a Reported values in mmol/L were converted to mg/dL by dividing cholesterol values by 0.02586 and TG values by 0.01130
b Change per year
cMedian values
d Included common, bulb, and internal segments
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personnel and patients remained blinded following the baseline
visit, a central laboratory reviewed LDL-C values and informed
the investigator if the atorvastatin treatment required modifica-
tion. Additional visits were scheduled for weeks 6, 13, 26, 39,
52, 65, 78, 91, and 104.
Safety follow-up phase
The follow-up phase will begin 1 day after the last dose of
study drug and end approximately 30 days later.
Procedures and assessments
Physical examination and laboratory analysis
A complete physical examination was conducted at baseline and
a symptom-directed (per patient report or examiner identified)
physical was performed at all subsequent visits. Vital signs,
including sitting blood pressure, heart rate, body temperature,
and weight, were measured at all visits. Blood and urine were
collected at all visits (except no urinalysis at visit 1), with a
fasting period of at least 12 h before the blood draw. The lipid
and inflammatory parameters to be assessed are listed in Table 2.
A 12-lead resting electrocardiogram (ECG) assessment was
performed at baseline and the final visit.
Carotid intima-media thickness
Carotid intima-media thickness was measured within 17 days
before baseline and at weeks 26, 52, 78, and 104 (or upon
premature discontinuation). CIMT was only measured upon
premature discontinuation if a patient received a minimum of
26weeks of studydrug treatment.Theprocedurewasdonebya
trained sonographer at a central facility within each of the
geographic locations of the participating sites using a standard-
ized protocol (Fig. 2). All facilities used the same device (GE
VIVID i equippedwith an 8-L probe). Amask tool was used to
allow proper repositioning during follow-up visits. After the
sonographer selected the regionof interest, theCIMTdetection
and measurement was fully automated.
Safety
Safety evaluations included physical examinations, vital signs,
clinical laboratory testing (hematology, chemistry, andurinalysis),
ECGmeasurements, and adverse eventmonitoring. Each adverse
event was rated by severity and relationship to the study drug.
Compliance
Compliance with dietary instructions was assessed at all
visits following visit 1 based on patient self-reporting. Each
patient was asked to return the previously dispensed study
drug bottle for documentation of study drug compliance.
Patients were considered to be compliant if they adhered to
≥80 % of dosing.
Endpoints
The primary efficacy variable is the rate of change from baseline
through week 104 of the mean posterior-wall IMTof the left and
right CCAs. The secondary efficacy variables are the rates of
change from baseline through week 104 in mean of the maximal
posterior-wall IMTof the left and right CCAs and the composite
of the CCAs, internal carotid, and carotid bifurcation. Additional
efficacy variables include:
Table 2 Lipid and inflammatory markers to be assessed
Lipid Markers Inflammatory Markers Lipid Particle Sizes and Concentrations by NMR Spectroscopy
Total-C hs-CRP VLDL (total, large, medium and small)
LDL-C (direct) LDL (total, IDL, large and small)








Apo B:Apo AII ratio
Apo CIII associated with
Apo B-containing lipoprotein particles
Apo apolipoprotein; C cholesterol; HDL high-density lipoprotein; hs-CRP high-sensitivity C-reactive protein; IDL intermediate-density lipoprotein;
LDL low-density lipoprotein; NMR nuclear magnetic resonance; TG triglyceride; VLDL very low-density lipoprotein
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1. Rate of change from baseline to week 104 in:
a. Mean of the median, 10th percentile, and 90th per-
centile posterior-wall IMT of the left and right CCAs
b.Mean cross-sectional area (calculated using posterior-
wall IMT and diameter) of the left and right CCAs
2. The occurrence of CVevents as a composite of CV mortal-
ity, nonfatal myocardial infarction (MI), and nonfatal stroke
3. The occurrence of CVevents as a composite of CV mortal-
ity, nonfatal MI, nonfatal stroke, coronary revascularization,
carotid endarterectomy/stenting, hospitalization for unstable
angina, and hospitalization for congestive heart failure
4. Change from baseline in lipid profile and inflammatory
markers listed in Table 2
Statistical considerations
Power analysis
A sample size of 300 to 350 patients per group provides 92 %
to 95 % power to detect a 0.014 mm/y change in CIMT, with a
2-sided α-level of 0.05, assuming a common standard
deviation of 0.045 mm/y and allowing for a 25 % dropout rate.
The power and sample size were revised from the initial
protocol (originally 400 patients per group) based on 1) a
reassessment of the literature, resulting in a lower standard
deviation for CIMT progression (originally 0.050), and 2) a
lower than expected discontinuation rate, resulting in a larger
evaluable sample than originally projected.
Outcome analysis
Means of demographic characteristics will be compared be-
tween treatment groups using a one-way analysis of variance
(ANOVA). The frequencies and percentages for demographic
characteristics will be compared between treatment groups using
a chi-square test. Baseline values for CIMT and efficacy labo-
ratory parameters will be compared between treatment groups
using a two-way ANOVAwith effects for baseline atorvastatin
dose and treatment group. Primary, secondary, and additional
CIMT variables assessing rates of change will be analyzed using
a repeated measures linear mixed-effects model with fixed
effects for baseline mean CIMT value, site, baseline atorvastatin
dose, treatment group, time, and the interaction between
Fig. 2 Scanning protocol
CCA 0 common carotid artery;
ICA 0 internal carotid artery
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treatment group and time. Time to first CV events will be
compared between treatment groups using the log-rank test
stratified by baseline atorvastatin dose. A Cox proportional
hazards model with baseline atorvastatin dose as a covariate
will be used to obtain the hazard ratio and 95 % confidence
interval for the hazard ratio. The percentage changes from
baseline in all efficacy laboratory parameters (except high-
sensitivity C-reactive protein [hs-CRP]) will be analyzed using
an analysis of covariance with baseline values (laboratory pa-
rameter corresponding to the efficacy variable being modeled)
as the covariate and baseline atorvastatin dose and treatment
group as effects. A non-parametric analysis will be performed to
evaluate the percentage changes from baseline in hs-CRP.Mean
changes from baseline in safety laboratory parameters will be
compared between treatment groups using a one-way ANOVA.
P values ≤0.05 will be considered statistically significant.
Results
The demographics and baseline characteristics of the study
population are shown for the treated patients in Table 3 and
clinical characteristics are shown in Table 4. The population
is not broken down by treatment group since the study is
ongoing, and hence blinded. The characteristics are in align-
ment with the targeted patient population, although the Apo
B level is surprisingly low in relation to LDL-C levels and
considering non-HDL-C levels. However, previous CIMT
studies may have used different measurements of LDL-C. It
is unclear how this parameter will affect the outcome and
interpretation of the study.
Table 3 Demographics and baseline characteristics of the total blinded
treated patient population
Variable Total Patients (n0676)
Male, n (%) 458 (67.8)
White race, n (%) 593 (87.7)
Age
Mean, y (SD) 60.8 (8.75)
Range, y 45–87
Mean BMI, kg/m2 (SD) 32.7 (5.81)




Mean lipid parameters, mg/dL (SD)
Total-C 157.9 (26.2)





Apo B 81.0 (15.6)
Apo AI 130.7 (17.9)
Apo AII 34.8 (5.7)
Apo CIII-lipoprotein Bb 1.6 (0.8)
hs-CRP, mg/L (SD) 4.1 (7.8)















VLDL TG, mg/dL (SD) 155.4 (83.2)
Apo apolipoprotein; BMI body mass index; C cholesterol; HDL high-
density lipoprotein; hs-CRP high-sensitivity C-reactive protein; IDL
intermediate-density lipoprotein; LDL low-density lipoprotein; TG tri-
glyceride; VLDL very low-density lipoprotein
a Includes all types of nicotine use
b Apo CIII associated with lipoproteins that contain Apo B, excluding
Apo CIII associated with HDL particles
Table 4 Clinical characteristics of the total blinded treated patient
population
Condition, n (%) Total Patients (n0676)
Angina 63 (9.3)
Cardiac arrhythmia 55 (8.1)
Carotid artery disease 44 (6.5)
Congestive heart failure 13 (1.9)
Coronary artery disease 146 (21.6)
Diabetes type 2 337 (49.9)
Emphysema/COPD 44 (6.5)
Hypertension 532 (78.7)
Myocardial infarction 72 (10.7)
Obesity 193 (28.6)
Peripheral vascular disease, arterial 16 (2.4)
Peripheral vascular disease, venous 5 (0.7)
Transient ischemic attack 13 (1.9)
Valvular heart disease 16 (2.4)
COPD chronic obstructive pulmonary disease
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Summary
In summary, the current study is novel in several ways:
& It is the first study to examine the effect of fenofibric
acid on CIMT.
& It is the first CIMT trial to select patients with controlled
LDL-C and elevated TG and low HDL-C as inclusion
criteria.
& Prospective analysis of LDL particle size and concen-
trations, as well as Apo B and Apo CIII on Apo B-
containing lipoprotein particles, may provide more in-
formation on the association of these parameters with
risk for CIMT progression compared with LDL-C.
& The trial was designed to address some of the limitations
of previous CIMT trials.
A beneficial outcome on CIMT after treatment would
provide evidence that fenofibric acid can not only improve
lipid parameters, but also have a positive effect on progres-
sion of subclinical atherosclerosis.
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